In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

When Opportunity Knocks: Eisai Turns To Business Development

Executive Summary

Starting in 2006, Eisai embarked on a bold campaign to reorient the company around cancer – with an emphasis on externally sourced innovation – that put aggressive business development front and center. Now as Eisai prepares to launch what may be its most transformative in-licensed product, the weight-loss therapy Belviq, signs of trouble have appeared in its trophy cancer franchise.

Advertisement

Related Content

CROs And Biopharma Weigh The Balance Of Risk And Responsibility
AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013
Affymax Considers Bankruptcy As Omontys Investigation Continues
Arena Finds Antidote For Belviq’s Theoretical Risk Of Valvulopathy In Mechanistic Studies
Takeda’s Strategic Run Up To Nycomed
Eisai Will Try For Halaven Label Expansion, Despite Phase III Failure
Epizyme Builds A Cancer Company At Mach Speed
Dacogen Leukemia Indication Would Require New Clinical Trial, FDA Tells Eisai

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel